Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ...

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced data from its Phase ...

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

Scientists report landmark "evolutionary double-bind" strategy to overcome treatment resistance in prostate cancer.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

Study is the first to directly quantify and validate a method of exploiting the way cancers evolve, both in the lab and through mathematical modelling ...

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) stock gained 3.9% in premarket trading Tuesday following positive clinical data from its Phase 1/2 study of MRT-2359 in combination with enzalutamide for ...